The Program in Cellular and Molecular Medicine at Boston Children’s Hospital is recognized worldwide for its discoveries that increase the body’s ability to fight disease and to heal.
Financial and Scientific Administrative Directors
Message from the Financial and Scientific Administrative Directors
Welcome to the website of the Program in Cellular and Molecular Medicine at Boston Children's Hospital.
Previously as the Immune Disease Institute and currently as the Program in Cellular and Molecular Medicine (PCMM) at Boston Children's Hospital, we are recognized worldwide for our discoveries that increase the body's ability to fight disease and to heal. We advance human health through research that has inflammation and the immune system as central themes. Our work is broad in focus and has implications for maintaining wellness and for treatment of a broad range of afflictions, from cancer to heart disease to infectious diseases to cystic fibrosis and beyond. In recent years, we have also contributed important basic science insights in the area of bioterrorism. As we conduct our research here, we also train undergraduates, graduate students, and postdoctoral fellows for leadership in teaching, research, and industry. We are actively involved in the transfer of new technologies for the development of medical treatments and cures.
As a part of Children’s Hospital Boston we have a host of resources and collaborative opportunities with both clinical and pre-clinical researchers at a world-class institution with whom we have historic roots.
Our affiliation with Harvard Medical School provides academic appointments for our investigators and integrates all our scientists into the world's leading network of biomedical research and education.
The National Institutes of Health and private donors are our partners and source of financial support. The generosity of donors has enabled these and many other breakthroughs, which illustrate the promise of PCMM's work for millions of patients:
- Using RNA interference to promote healing in mice that were infected with a form of hepatitis - the first time this therapy has been shown to work in animals, promising hope for patients thus afflicted.
- Revealing the genetics driving our immune system's remarkable ability to generate millions of protective antibodies. Failure in this complicated DNA breakage and repair process is associated with lymphomas and other cancers.
- Tracing the action of proteins that determine if the body rejects or tolerates transplanted tissue. This advance points to treatments that selectively suppress the immune system without the complications of drugs currently given to transplant patients.
- Imaging a dendritic cell as it alerts other immune cells to invasion of the body. Our researchers are seeking to strengthen this alarm, which provides immune cells with the intelligence they require to prevent disease.
- Producing the first crystal structures of the integrins binding intercellular adhesion molecules. Stronger therapies, with fewer side effects, are now possible to prevent immune cells from attacking healthy tissue, characteristic of autoimmune diseases that afflict tens of millions worldwide.
- Combating the bioterrorism threat associated with viral infectious agents through a technique known as RNA interference. This powerful genetic strategy suppresses the replication of viruses and may have important therapeutic implications.
We are about scientific excellence and vision in pursuit of tomorrow's cures. We invite you to tour our web site and share in the excitement of our science. The site provides a wealth of detail about our work at the frontiers of biomedical knowledge and the pre-eminent scientists who are leading this vitally important work. After exploring the site, we are certain that you will recognize the depth and power of our commitment to increase mankind's understanding of how wellness can be maintained and how a wide variety of diseases can be treated and even cured.
Alexander Shtifman, Ph.D. - Scientific Administrative Director
Stephen Carriuolo - Financial Administrative Director